191 related articles for article (PubMed ID: 26226846)
21. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer.
Guo M; Luo G; Liu C; Cheng H; Lu Y; Jin K; Liu Z; Long J; Liu L; Xu J; Huang D; Ni Q; Yu X
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399694
[TBL] [Abstract][Full Text] [Related]
22. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
23. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
[TBL] [Abstract][Full Text] [Related]
24. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
[TBL] [Abstract][Full Text] [Related]
25. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
Connor AA; Denroche RE; Jang GH; Timms L; Kalimuthu SN; Selander I; McPherson T; Wilson GW; Chan-Seng-Yue MA; Borozan I; Ferretti V; Grant RC; Lungu IM; Costello E; Greenhalf W; Palmer D; Ghaneh P; Neoptolemos JP; Buchler M; Petersen G; Thayer S; Hollingsworth MA; Sherker A; Durocher D; Dhani N; Hedley D; Serra S; Pollett A; Roehrl MHA; Bavi P; Bartlett JMS; Cleary S; Wilson JM; Alexandrov LB; Moore M; Wouters BG; McPherson JD; Notta F; Stein LD; Gallinger S
JAMA Oncol; 2017 Jun; 3(6):774-783. PubMed ID: 27768182
[TBL] [Abstract][Full Text] [Related]
26. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
[TBL] [Abstract][Full Text] [Related]
27. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
[TBL] [Abstract][Full Text] [Related]
28. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer.
Dong X; Li Y; Hess KR; Abbruzzese JL; Li D
Oncologist; 2011; 16(1):61-70. PubMed ID: 21212431
[TBL] [Abstract][Full Text] [Related]
29. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
[TBL] [Abstract][Full Text] [Related]
30. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
31. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.
Nagao Y; Hisaoka M; Matsuyama A; Kanemitsu S; Hamada T; Fukuyama T; Nakano R; Uchiyama A; Kawamoto M; Yamaguchi K; Hashimoto H
Mod Pathol; 2012 Jan; 25(1):112-21. PubMed ID: 21983937
[TBL] [Abstract][Full Text] [Related]
32. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
33. DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance.
Liu W; Shia J; Gönen M; Lowery MA; O'Reilly EM; Klimstra DS
Pancreas; 2014 Nov; 43(8):1264-70. PubMed ID: 25058881
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.
Lee SH; Kim H; Hwang JH; Lee HS; Cho JY; Yoon YS; Han HS
Pathol Int; 2012 Mar; 62(3):167-75. PubMed ID: 22360504
[TBL] [Abstract][Full Text] [Related]
35. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
36. A correlation study of mismatch repair immunohistochemical protein expression of pancreatic solid tumors in cytology cell blocks and matching surgical specimens.
Teodosescu A; Chan I; Elder J; Wu M
Diagn Cytopathol; 2021 Jun; 49(6):700-705. PubMed ID: 33615705
[TBL] [Abstract][Full Text] [Related]
37. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J
Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699
[TBL] [Abstract][Full Text] [Related]
38. Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy.
Yekebas EF; Bogoevski D; Bubenheim M; Link BC; Kaifi JT; Wachowiak R; Mann O; Kutup A; Cataldegirmen G; Wolfram L; Erbersdobler A; Klein C; Pantel K; Izbicki JR
World J Gastroenterol; 2006 Oct; 12(40):6515-21. PubMed ID: 17072983
[TBL] [Abstract][Full Text] [Related]
39. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
40. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]